Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Alzheimer's Disease
jRCT2031260366Phase 3Not yet recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Trontinemab with Placebo (2 arms). Primary endpoint: Time to Progression. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
trontinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031260366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260366.